Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca ( (GB:AZN) ) has shared an update.
AstraZeneca has filed its 2025 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission, making the document available on both the regulator’s and the company’s websites. The company is also offering hard copies of its complete audited financial statements free of charge to security holders upon request, underlining its ongoing disclosure obligations to investors and regulators.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16781.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, U.K., focused on discovering, developing, and commercialising prescription medicines. Its core therapeutic areas are Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology, with products sold in more than 125 countries.
Average Trading Volume: 2,535,622
Technical Sentiment Signal: Buy
Current Market Cap: £237.6B
For a thorough assessment of AZN stock, go to TipRanks’ Stock Analysis page.